Table 2. Summary of the randomized clinical trials of lymph node dissection for resectable NSCLC.
| Trial | Country | Patients/study design/number of patients | Control arm | Median follow-up period (month) | 5-year survival | DFS | Morbidity | Mortality | Year | Reference |
|---|---|---|---|---|---|---|---|---|---|---|
| Izbicki | Germany | Operable NSCLC/RCT/N=169 | Lymph node sampling | 47.5 | 65.8% (54.8%) | Median DFS: 48 months (median DFS: 24 months) | NA | NA | 1998 | (10) |
| Sugi | Japan | Clinical N0 peripheral NSCLC less than 2 cm in diameter/RCT/N=115 | Lymph node sampling | 65 | 81.4% (83.9%) | NA | 26.8%* (3.4%) | 0% (0%) | 1998 | (11) |
| Wu | China | Clinical stage I-IIIA NSCLC/RCT/N=471 | Lymph node sampling | 43 | 48.37%* (36.98%) | NA | NA | 0.31% (0%) | 2002 | (14) |
| Daring Allen | America | Surgical N0 or N1 (less than hilar) NSCLC/RCT/N=1,023 | Lymph node sampling | 78 | MST: 8.5 years (MST: 8.1 years) | 5-year DFS: 68% (5-year DFS: 69%) | 0.76% (2.0%) | 38% (38%) | 2011 | (12,13) |
| Zhang | China | Clinical stage I-IIIA NSCLC/RCT/N=202 | Minimal mediastinal dissection (mediastinal structures were not skeletonized) | NA | 55.7%* (37.7%) | NA | 14.7% (14.0%) | 2.1% (1.9%) | 2013 | (15) |
Parentheses: data for control arm; *, P<0.05. DFS, disease-free survival; NSCLC, non-small cell lung cancer; RCT, randomized clinical trial; N, number; MST, median survival time; NA, not available.